TA149

Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149)

  • Technology appraisals TA149
  • Issued: June 2008
    • Carmustine implants for the treatment of recurrent glioblastoma multiforme

      NICE is unable to recommend the use in the NHS of carmustine implantsas an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology.

      This page was last updated: 30 March 2010

    • Guidance formats

      Query

Implementation tools and resources

  • None available

See this guidance in practice

Patient

The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.

Quick Reference Guide

The quick reference guide presents recommendations for health professionals

NICE Guidance

The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.

Full Guidance

The published full clinical guidance for specialists with background, evidence, recommendations and methods used.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright @ 2012 National Institute for Health and Clinical Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright @ 2012 National Institute for Health and Clinical Excellence. All rights reserved.